- Medicine Name: Rezlidhia
- Generic Name: Olutasidenib
- Dosage Form & Strength: Capsules: 150 mg
- Manufactured By: Rigel and Forma Therapeutics, Inc.
Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor used for treating adults with isocitrate dehydrogenase-1 (IDH1)-mutated Acute Myeloid Leukemia (AML) when the cancer has returned or has not improved after previous therapeutic option(s).
Recommended Dosage: The recommended dosage is 150 mg taken by mouth twice daily until disease progression or unacceptable toxicity. Administer Rezlidhia capsules orally at around the same time each day. Avoid taking two doses within 8 hours. Take on an empty stomach either 60 minutes before or 120 minutes after a meal. Swallow capsules whole. It is not advisable to open, break, or chew the capsules. For those without disease progression or unacceptable toxicity, treatment for at least 6 months to allow time for clinical response.
If any dose is vomited, avoid administering a replacement dose; wait until the very next scheduled dose is due. In case a dose is missed or not taken at around the standard time, administer the dose promptly and at least 8 hours before the next scheduled dose. Return to the standard schedule the following day.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.